Press releases
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo Q1 2024 Interim Report
- Report from Orexo AB's annual general meeting, 26 April 2024
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
More ▼
Key statistics
On Friday, Orexo AB (C5G:FRA) closed at 1.83, -3.99% below its 52-week high of 1.90, set on May 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.82 |
---|---|
High | 1.83 |
Low | 1.82 |
Bid | 1.86 |
Offer | 1.96 |
Previous close | 1.84 |
Average volume | 3.00 |
---|---|
Shares outstanding | 34.71m |
Free float | 27.47m |
P/E (TTM) | -- |
Market cap | 725.45m SEK |
EPS (TTM) | -2.13 SEK |
Data delayed at least 15 minutes, as of Jun 07 2024 12:33 BST.
More ▼